'Annual Conference on EU Law in the Pharmaceutical Sector 2025' returns to Brussels and online with 25% IPKat readers’ discount
![]() |
Kats of Brussels |
Taking place in Brussels and online on 27 and 28 March 2025, this event will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest regulatory developments, legislative initiatives and case law.
The programme features the following topics:
- Key priorities of the new European Commission
- The European Health Union
- The European Health Data Space
- Ongoing revision of the EU Pharma Regulatory legal framework
- Towards a Critical Medicines Act
- Biotechnology and the future of research and pharmaceutical innovation
- Artificial intelligence in the life science sector
- Medical devices, in vitro diagnostics and borderline products
- SoHo
- Pricing and HTA
- EMA recent activities
There will also be a roundtable discussion tackling “How to reach a sustainable, digital and high-tech life science ecosystem” and focusing on “Navigating between data exclusivity, IP protection and fair competition”.
ERA is also offering IPKat readers a generous 25% discount in the registration fee, using VIP code IPKAT2025ERA at checkout. The discount can be combined with the early bird discount (where applicable) but cannot be used alongside other discounts.
To learn more and to register, click here.
'Annual Conference on EU Law in the Pharmaceutical Sector 2025' returns to Brussels and online with 25% IPKat readers’ discount
Reviewed by Eleonora Rosati
on
Thursday, February 06, 2025
Rating:

No comments:
All comments must be moderated by a member of the IPKat team before they appear on the blog. Comments will not be allowed if the contravene the IPKat policy that readers' comments should not be obscene or defamatory; they should not consist of ad hominem attacks on members of the blog team or other comment-posters and they should make a constructive contribution to the discussion of the post on which they purport to comment.
It is also the IPKat policy that comments should not be made completely anonymously, and users should use a consistent name or pseudonym (which should not itself be defamatory or obscene, or that of another real person), either in the "identity" field, or at the beginning of the comment. Current practice is to, however, allow a limited number of comments that contravene this policy, provided that the comment has a high degree of relevance and the comment chain does not become too difficult to follow.
Learn more here: http://ipkitten.blogspot.com/p/want-to-complain.html